

Syngene

Ref: Syn/CS/SE/Reg 30/2024-25/Feb/07

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

February 21, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Update on pre-approval and cGMP inspection by United States Food & Drug Administration (USFDA)

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, this is to inform you that the USFDA conducted a pre-approval and cGMP inspection covering commercial manufacturing activities for the US market, at the Bengaluru facilities from February 10, 2025 till February 20, 2025. On conclusion of the inspection, the USFDA issued Form 483 with 5 (Five) observations. The Company will work closely with USFDA and remains committed to addressing these observations comprehensively within the stipulated time.

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

Kindly take this intimation on record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Head Legal, Company Secretary & Compliance Officer